688488 Jiangsu Aidea Pharmaceutical
- 9.37
- +1.47+18.61%
Jiangsu Aidea Pharmaceutical News
Jiangsu Aidea Pharmaceutical Withdraws Marketing Authorization Application for HIV Tablets
Jiangsu Aidea Pharmaceutical (688488.SH): Withdrawal of the new indication application for Aino Weilin tablets.
Gelonghui September 26th | jiangsu aidea pharmaceutical (688488.SH) announced that the company has scientifically formulated differentiated market strategy based on evidence-based medicine data, product characteristics, patent duration, etc. for antiretroviral drugs. According to the company's market strategy, the company has proactively applied to withdraw the marketing authorization application for the new indication of enofovir tablets, and has recently obtained approval from the National Medical Products Administration. As of the date of this announcement, the single-compound formulation of enofoside tablets containing enofoside as an ingredient has made smooth progress in the application for new indications, and its marketing authorization application has completed the technical review work, and is currently in the process of document preparation and review and approval. The company will continue
Star Evening News | Xi'an Bright Laser Technologies plans to invest 1 billion yuan to build a material production line. Jiangsu Aidea Pharmaceutical has completed the acquisition of 31.161% equity of Nanda Pharmaceuticals.
1. Guangdong Jiayuan Technology signed the "Investment Intention Termination Agreement" with the Meixian District People's Government of Meizhou City; 2. Xi'an Bright Laser Technologies, opt machine vision tech co., ltd., NAIKE Equipment disclosed the repurchase plan; 3. Shanghai Allist Pharmaceuticals Co., Ltd.: AST2303 slice obtained the drug clinical trial approval notice.
Aidea Pharma Pledges Subsidiary's 51% Stake for 90 Million Yuan Loan; Shares Drop 5%
Jiangsu Aidea Pharmaceutical 2024 Half-Year Report
Summary of jiangsu aidea pharmaceutical's 2024 Interim Report
Gelonghui announcement selection | Hubei Heyuan Gas Co., Ltd.: plans to invest 2.2 billion yuan in the construction of electronic gas center and global headquarters in Donghu Comprehensive Bonded Zone; Sailun Group: net income in the first half of the yea
Signing Project: Harbin Pharmaceutical Group (600664.SH): plans to invest 9.162 million yuan in the renovation project of Harbin Pharmaceutical Institute of Traditional Chinese Medicine; plans to invest 10.06 million yuan in the heating network project in the Nanzhiliu Factory of Harbin Pharmaceutical Co., Ltd. Chongqing Taiji Industry (600129.SH): Subsidiary Tongjunge Pharmaceutical Factory plans to build Phase I of the new plant area; Hubei Heyuan Gas Co., Ltd. (002971.SZ): plans to invest 2.2 billion yuan in the construction of the electronic gas center and global headquarters in Donghu Comprehensive Bonded Zone; Hunan Boyun New Materials (002297.SZ): plans to invest 60.006 million yuan in the renovation of Boyun New Materials Innovation Industrial Park.
Jiangsu Aidea Pharmaceutical (688488.SH): plans to privately place shares to the controlling shareholder to raise no more than 0.1 billion yuan.
On August 22nd, Aidea Pharmaceuticals (688488.SH) announced the plan to issue A-shares to specific individuals in 2024. The recipient of this issuance is Mr. Fu Heliang, who is one of the company's actual controllers. Mr. Fu intends to subscribe to all stocks issued in this offering using cash. As Mr. Fu Heliang is a related party of the company, this issuance of stocks to specific individuals constitutes a related transaction. The total amount of funds raised through this issuance to specific individuals does not exceed 0.1 billion yuan (including this amount), and the net amount of funds raised after deducting the relevant issuance expenses is intended to be used entirely for supplementary working capital.
Jiangsu Aidea Pharmaceutical Co., Ltd. (SHSE:688488) Insiders, Who Hold 28% of the Firm Would Be Disappointed by the Recent Pullback
Jiangsu Aidea Pharmaceutical (688488.SH): The actual controller and president cumulatively increased their shareholding by 0.11%.
Jiangsu Aidea Pharmaceutical (688488.SH) announced that on July 10, 2024, the actual controller and president cumulatively increased their holdings of the company's shares by 446,013 shares, accounting for 0.11% of the total share capital of the company, through the Shanghai Stock Exchange trading system in a centralized bidding manner, with a total investment of RMB 4.2352 million, which has exceeded half of the minimum amount of this shareholding plan. The main body of the shareholding will continue to increase the company's shares according to the relevant shareholding plan within the implementation period of the shareholding plan.
Jiangsu Aidea Pharmaceutical (688488.SH) has currently no relevant cooperation with Gilead.
Jiangsu Aidea Pharmaceutical (688488.SH) stated on the interactive platform on June 27th that the company currently has no related cooperation with Gilead.
Here's Why Jiangsu Aidea Pharmaceutical (SHSE:688488) Can Afford Some Debt
Jiangsu Aidea Pharmaceutical (688488.SH): Approval notice for the listing application of Active Pharmaceutical Ingredient Enavuirin received.
On June 3rd, Gelunhui reported that Jiangsu Aidea Pharmaceutical (688488.SH) announced that its wholly-owned subsidiary, Yangzhou Aidi Pharmaceutical Technology Co., Ltd. (collectively referred to as 'Aideo Pharmaceutical' or 'the Company'), received the 'Approval Notice for the Listing Application of Chemical Raw Materials for Enoxavir' (Notice No.: 2024YS00494) issued by the State Drug Administration. The chemical raw material Enoxavir of the company has obtained the 'Approval Notice for the Listing Application of Chemical Raw Materials', indicating that the raw material has met the relevant drug evaluation technical standards of the country, and has been approved for use in domestic formulations, and can be subsequently applied to the production of Enoxavir tablets and Ennomitin tablets.
Eddy Pharmaceuticals (688488.SH) reported first-quarter results with a net loss of 13.6069 million yuan
Eddy Pharmaceuticals (688488.SH) released its report for the first quarter of 2024. The company achieved operating revenue during the reporting period...
Insiders Are the Top Stockholders in Jiangsu Aidea Pharmaceutical Co., Ltd. (SHSE:688488), and the Recent 12% Drop Might Have Disappointed Them
Eddy Pharmaceuticals (688488.SH) is planning a major asset restructuring to acquire 31.16% of Nanda Pharmaceutical's shares to take control of it
Eddy Pharmaceutical (688488.SH) announced that recently, the company and Nanjing Nanda Pharmaceutical Co., Ltd. (hereinafter referred to as...
Eddy Pharmaceuticals (688488.SH): Net loss of 76.0695 million yuan in 2023
Gelonghui, April 15 | Eddy Pharmaceutical (688488.SH) released its 2023 annual report. During the reporting period, it achieved operating income of 411 million yuan, an increase of 68.44% over the previous year; net profit attributable to shareholders of listed companies - 76.695 million yuan; and basic earnings per share - 0.18 yuan.
What Jiangsu Aidea Pharmaceutical Co., Ltd.'s (SHSE:688488) 27% Share Price Gain Is Not Telling You
Eddy Pharmaceuticals (688488.SH): Pre-loss of 63 million yuan to 90 million yuan in 2023
Gelonghui, January 30丨Eddy Pharmaceutical (688488.SH) announced its 2023 annual results forecast. According to preliminary estimates by the finance department, the company's annual revenue for 2023 is expected to be about 416.585 million yuan, an increase of about 172.3612 million yuan compared with the previous year, an increase of about 70.58% over the previous year. Among them, revenue from innovative anti-HIV drugs is expected to be 73.5788 million yuan, an increase of 119.67% year on year. Revenue from crude human protein products is estimated to be 262.20.29 million yuan, an increase of 82.82% year on year; Realize your return for the year 2023
Eddy Pharmaceutical (688488.SH) received a warning letter from the Jiangsu Securities Regulatory Bureau
Zhitong Finance App News, Eddy Pharmaceutical (688488.SH) issued an announcement. The company recently received the Jiangsu Securities Regulatory Bureau's decision on administrative supervision measures “Jiangsu Securities Regulatory Bureau's Decision on Issuing Warning Letter Measures against Jiangsu Eddy Pharmaceutical Co., Ltd.” ([2024] No. 25). After investigation, on August 19, 2020, the company held the 11th meeting of the first board of directors and the 7th meeting of the first board of supervisors to review and pass the “Proposal on Using Some Idle Raised Funds for Cash Management”, agreeing to use no more than one person within 12 months from the date of review and approval by the company's board of directors and board of supervisors
Analysis
Price Target
No Data
No Data